CY1123697T1 - Θεραπεια της amd με χρηση της παραλλαγης aav2 με αφλιβερσεπτη - Google Patents

Θεραπεια της amd με χρηση της παραλλαγης aav2 με αφλιβερσεπτη

Info

Publication number
CY1123697T1
CY1123697T1 CY20201101133T CY201101133T CY1123697T1 CY 1123697 T1 CY1123697 T1 CY 1123697T1 CY 20201101133 T CY20201101133 T CY 20201101133T CY 201101133 T CY201101133 T CY 201101133T CY 1123697 T1 CY1123697 T1 CY 1123697T1
Authority
CY
Cyprus
Prior art keywords
amd
aflivercept
treatment
aav2 variant
aav2
Prior art date
Application number
CY20201101133T
Other languages
English (en)
Inventor
Mark Blumenkranz
Mehdi Gasmi
Original Assignee
Adverum Biotechnologies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adverum Biotechnologies, Inc. filed Critical Adverum Biotechnologies, Inc.
Publication of CY1123697T1 publication Critical patent/CY1123697T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Mycology (AREA)
  • Hematology (AREA)

Abstract

Η παρούσα αποκάλυψη παρέχει φαρμακευτικές συνθέσεις και μεθόδους αυτών για τη θεραπεία της ηλικιακής εκφύλισης της ωχράς κηλίδας (AMD) σε ένα υποκείμενο δια χορήγησης εντός του υαλοειδούς μιας φαρμακευτικής σύνθεσης προσαρμοσμένης για γονιδιακή θεραπεία, που περιλαμβάνει έναν φορέα που έχει μία αλληλουχία νουκλεϊκών οξέων που κωδικοποιεί αφλιβερσέπτη.
CY20201101133T 2016-06-16 2020-11-30 Θεραπεια της amd με χρηση της παραλλαγης aav2 με αφλιβερσεπτη CY1123697T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662351234P 2016-06-16 2016-06-16
PCT/US2017/038003 WO2017218974A2 (en) 2016-06-16 2017-06-16 Treatment of amd using aav2 variant with aflibercept

Publications (1)

Publication Number Publication Date
CY1123697T1 true CY1123697T1 (el) 2022-03-24

Family

ID=60663653

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201101133T CY1123697T1 (el) 2016-06-16 2020-11-30 Θεραπεια της amd με χρηση της παραλλαγης aav2 με αφλιβερσεπτη

Country Status (22)

Country Link
US (2) US20190151409A1 (el)
EP (2) EP3471780B1 (el)
JP (3) JP6814822B2 (el)
KR (2) KR102218265B1 (el)
CN (2) CN109641065A (el)
AU (2) AU2017286673B2 (el)
BR (1) BR112018076124A2 (el)
CA (1) CA3027737A1 (el)
CY (1) CY1123697T1 (el)
DK (1) DK3471780T3 (el)
ES (1) ES2840059T3 (el)
HR (1) HRP20201842T1 (el)
HU (1) HUE051953T2 (el)
IL (2) IL263686B (el)
LT (1) LT3471780T (el)
MX (2) MX2018015512A (el)
PT (1) PT3471780T (el)
RS (1) RS61311B1 (el)
SG (1) SG11201811232XA (el)
SI (1) SI3471780T1 (el)
WO (1) WO2017218974A2 (el)
ZA (1) ZA201808538B (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3119798B1 (en) 2014-03-17 2020-08-05 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression in cone cells
EA201791939A1 (ru) 2015-03-02 2018-01-31 Адверум Байотекнолоджиз, Инк. Композиции и способы интравитреальной доставки полинуклеотидов в колбочки сетчатки
AU2018234918B2 (en) 2017-03-17 2023-11-02 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression
CN107537026A (zh) * 2017-08-31 2018-01-05 中山大学中山眼科中心 Vegf‑b的应用
CN107661492A (zh) * 2017-08-31 2018-02-06 中山大学中山眼科中心 Vegf‑b的新用途
CA3079565A1 (en) * 2017-10-18 2019-04-25 Regenxbio Inc. Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified vegf-trap
EP3717636B1 (en) 2017-11-27 2023-03-08 4D Molecular Therapeutics Inc. Adeno-associated virus variant capsids and use for inhibiting angiogenesis
SG11202005618WA (en) 2017-12-19 2020-07-29 Akouos Inc Aav-mediated delivery of therapeutic antibodies to the inner ear
EP3773677A1 (en) * 2018-04-12 2021-02-17 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Anti-aging compositions and methods of use
EP3934698A1 (en) * 2019-03-04 2022-01-12 Adverum Biotechnologies, Inc. Sequential intravitreal administration of aav gene therapy to contralateral eyes
AU2019465527A1 (en) * 2019-09-11 2022-03-10 Adverum Biotechnologies, Inc. Methods of treating ocular neovascular diseases using AAV2 variants encoding aflibercept
KR20220062353A (ko) * 2019-09-11 2022-05-16 애드베룸 바이오테크놀로지스, 인코포레이티드 아플리베르셉트를 코딩하는 aav2 변이체를 사용하여 안구 신생혈관 질환을 치료하는 방법
US11400039B2 (en) * 2020-01-16 2022-08-02 James W. Hill Changing eye color by gene transduction
CN113817775B (zh) * 2020-08-25 2023-02-17 南京吉迈生物技术有限公司 修饰的阿柏西普、组合物、方法及其在基因治疗中的应用
JP2021049374A (ja) * 2020-12-09 2021-04-01 株式会社三洋物産 遊技機
BR112023019056A2 (pt) * 2021-04-27 2024-01-16 Adverum Biotechnologies Inc Métodos para tratar doenças oculares usando variantes de aav2 que codificam aflibercepte

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3693025B1 (en) * 2011-04-22 2021-10-13 The Regents of The University of California Adeno-associated virus virions with variant capsid and methods of use thereof
ES2753135T3 (es) * 2012-05-07 2020-04-07 Allergan Inc Método de tratamiento de DMAE en pacientes resistentes a terapia anti-VEGF
TWI698240B (zh) * 2012-05-15 2020-07-11 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
KR20230152151A (ko) * 2013-07-12 2023-11-02 이베릭 바이오, 인크. 안과적 질환을 치료하거나 예방하기 위한 방법
AU2014337135B2 (en) 2013-10-18 2019-09-19 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of a VEGF antagonist and an anti-CTLA-4 antibody
EA201791939A1 (ru) * 2015-03-02 2018-01-31 Адверум Байотекнолоджиз, Инк. Композиции и способы интравитреальной доставки полинуклеотидов в колбочки сетчатки

Also Published As

Publication number Publication date
AU2021225178A1 (en) 2021-09-30
US20220265740A1 (en) 2022-08-25
MX2022004786A (es) 2022-05-16
RS61311B1 (sr) 2021-02-26
KR20190037228A (ko) 2019-04-05
CA3027737A1 (en) 2017-12-21
HUE051953T2 (hu) 2021-04-28
IL263686B (en) 2021-02-28
PT3471780T (pt) 2020-12-17
WO2017218974A3 (en) 2018-01-25
SG11201811232XA (en) 2019-01-30
AU2017286673A1 (en) 2019-01-31
IL279919A (en) 2021-03-01
JP2020203941A (ja) 2020-12-24
JP2022137244A (ja) 2022-09-21
ZA201808538B (en) 2021-04-28
IL263686A (en) 2019-01-31
ES2840059T3 (es) 2021-07-06
HRP20201842T1 (hr) 2021-04-16
BR112018076124A2 (pt) 2019-03-26
CN109641065A (zh) 2019-04-16
EP3471780A4 (en) 2019-04-24
AU2017286673B2 (en) 2021-06-24
EP3795181A1 (en) 2021-03-24
WO2017218974A2 (en) 2017-12-21
EP3471780B1 (en) 2020-10-28
CN117531025A (zh) 2024-02-09
MX2018015512A (es) 2019-04-24
SI3471780T1 (sl) 2021-03-31
KR20210021113A (ko) 2021-02-24
DK3471780T3 (da) 2020-11-23
US20190151409A1 (en) 2019-05-23
JP6814822B2 (ja) 2021-01-20
JP2019521990A (ja) 2019-08-08
LT3471780T (lt) 2021-01-25
EP3471780A2 (en) 2019-04-24
KR102218265B1 (ko) 2021-02-25

Similar Documents

Publication Publication Date Title
CY1123697T1 (el) Θεραπεια της amd με χρηση της παραλλαγης aav2 με αφλιβερσεπτη
CY1125084T1 (el) Εμβολια νουκλεϊκου οξεος
CY1124867T1 (el) Αντισωματα μονης περιοχης που κατευθυνονται εναντι ενδοκυτταρικων αντιγονων
CY1124252T1 (el) Anti-lag3 αντισωματα και θραυσματα συνδεσης αντιγονου
CY1123642T1 (el) Αντισωματα enanti-pd-1
PH12019500709A1 (en) Anti-lag-3 antibodies and methods of use thereof
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
CY1124806T1 (el) Αντισωματα enanti-cd40 και χρησεις αυτων
EA201890630A1 (ru) Антитела против pd-1 и способы их применения
CY1124588T1 (el) Γενετικο κατασκευασμα
EP4241784A3 (en) Artificial nucleic acid molecules for improved protein expression
WO2015109124A3 (en) Immunomodulatory agents
CY1120772T1 (el) ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ
CY1123963T1 (el) Καινοτομα πολυμερικα προφαρμακα hgh
PH12019500209A1 (en) Methods and compositions for gene expression in plants
AR099837A1 (es) Terapia génica para la retinitis pigmentaria
ZA201506093B (en) Methods and pharmaceutical composition for the treatment and the prevention of cardiomyopathy due to energy failure
CY1123947T1 (el) Βελτιστοποιημενος υποκινητης rpe65 και βελτιστοποιημενες κωδικοποιητικες αλληλουχιες
CY1121734T1 (el) ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ
CY1124667T1 (el) Τροποποιημενο rna που κωδικοποιει πολυπεπτιδια vegf-a, φαρμακοτεχνικες μορφες, και χρησεις που σχετιζονται με αυτα
EA201791560A1 (ru) Порошковый состав для интраназального введения для лечения гипогликемии
CY1120997T1 (el) Πρωτεϊνες συντηξης uti
EA202090014A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
MX2018005154A (es) Anticuerpos de dominio unico dirigidos contra el virus de la inmunodeficiencia humana.